Security Snapshot

HERON THERAPEUTICS, INC. /DE/ - Common Stock (HRTX) Institutional Ownership

CUSIP: 427746102

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

170

Shares (Excl. Options)

156,361,964

Price

$1.30

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
HRTX on Nasdaq
Shares outstanding
182,615,507
Price per share
$0.80
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
156,361,964
Total reported value
$203,256,534
% of total 13F portfolios
0%
Share change
+3,990,560
Value change
+$5,483,359
Number of holders
170
Price from insider filings
$0.80
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • HRTX - HERON THERAPEUTICS, INC. /DE/ - Common Stock is tracked under CUSIP 427746102.
  • 170 institutions reported positions in Q4 2025.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 170 to 18 between Q4 2025 and Q1 2026.
  • Reported value moved from $203,256,534 to $3,451,400.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 170 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 427746102?
CUSIP 427746102 identifies HRTX - HERON THERAPEUTICS, INC. /DE/ - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of HERON THERAPEUTICS, INC. /DE/ - Common Stock (HRTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Rubric Capital Management LP 16% -8.9% $37,859,003 +$1,192,086 30,046,828 +3.3% Rubric Capital Management LP 15 Oct 2025
Clearline Capital LP 6.7% +28% $18,108,154 +$3,733,614 12,235,239 +26% Clearline Capital LP 31 Dec 2025

As of 31 Dec 2025, 170 institutional investors reported holding 156,361,964 shares of HERON THERAPEUTICS, INC. /DE/ - Common Stock (HRTX). This represents 86% of the company’s total 182,615,507 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of HERON THERAPEUTICS, INC. /DE/ - Common Stock (HRTX) together control 77% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Rubric Capital Management LP 16% 30,046,828 +3.3% 0.47% $39,060,876
Clearline Capital LP 6.7% 12,235,239 +26% 1.2% $15,905,811
ADAGE CAPITAL PARTNERS GP, L.L.C. 6.1% 11,185,325 +9.2% 0.02% $14,540,923
BlackRock, Inc. 5.6% 10,218,236 +2.3% 0% $13,283,708
VANGUARD GROUP INC 5.4% 9,820,384 +16% 0% $12,766,499
Velan Capital Investment Management LP 4.8% 8,753,290 0% 6.6% $11,379,277
MILLENNIUM MANAGEMENT LLC 3.9% 7,169,908 +2785% 0.01% $9,320,880
PALISADE CAPITAL MANAGEMENT, LP 3.5% 6,326,113 -14% 0.24% $8,223,947
TANG CAPITAL MANAGEMENT LLC 3.4% 6,250,000 +81% 0.4% $8,125,000
Tejara Capital Ltd 2.8% 5,131,426 +12% 2.8% $6,670,854
GEODE CAPITAL MANAGEMENT, LLC 2.2% 4,081,222 +12% 0% $5,306,435
STATE STREET CORP 2.1% 3,778,043 +3.5% 0% $4,911,456
JW Asset Management, LLC 2% 3,671,073 +11% 1.6% $4,772,395
Congress Park Capital LLC 1.7% 3,067,475 +6.1% 1.2% $3,987,718
D. E. Shaw & Co., Inc. 1.6% 3,004,640 -2.7% 0% $3,906,032
NEW YORK STATE COMMON RETIREMENT FUND 1.4% 2,576,716 0% 0% $3,349,731
CITADEL ADVISORS LLC 1.1% 2,095,045 -23% 0% $2,723,559
UBS Group AG 1.1% 2,091,669 -29% 0% $2,719,170
RENAISSANCE TECHNOLOGIES LLC 1% 1,915,900 -33% 0% $2,490,670
Pale Fire Capital SE 0.8% 1,469,655 +212% 0.25% $1,910,552
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.78% 1,415,336 +11% 0% $1,839,937
JANE STREET GROUP, LLC 0.75% 1,367,891 +521% 0% $1,778,259
Stonepine Capital Management, LLC 0.68% 1,237,802 +46% 1.3% $1,609,143
Monaco Asset Management SAM 0.68% 1,233,022 +23% 0.48% $1,602,929
NORTHERN TRUST CORP 0.6% 1,091,411 -5.7% 0% $1,418,835

Institutional Holders of HERON THERAPEUTICS, INC. /DE/ - Common Stock (HRTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 4,313,128 $3,451,400 +$458,943 $0.80 18
2025 Q4 156,361,964 $203,256,534 +$5,483,359 $1.30 170
2025 Q3 152,658,767 $192,362,843 +$22,498,799 $1.26 171
2025 Q2 131,463,843 $272,131,676 +$12,999,478 $2.07 170
2025 Q1 124,770,231 $274,489,898 +$21,979,195 $2.20 164
2024 Q4 114,941,581 $175,829,179 -$13,146,397 $1.53 161
2024 Q3 121,816,811 $242,421,216 -$29,164,536 $1.99 169
2024 Q2 129,609,461 $453,638,008 +$35,415,047 $3.50 189
2024 Q1 119,262,673 $330,361,469 +$19,698,437 $2.77 157
2023 Q4 112,451,511 $191,165,565 +$1,074,277 $1.70 149
2023 Q3 118,378,841 $121,934,068 +$19,982,956 $1.03 138
2023 Q2 98,652,577 $114,435,495 -$11,706,623 $1.16 143
2023 Q1 107,852,430 $162,855,915 -$15,688,602 $1.51 153
2022 Q4 115,831,665 $289,582,111 -$29,877,564 $2.50 175
2022 Q3 121,963,764 $514,346,608 +$45,998,596 $4.22 178
2022 Q2 115,204,514 $321,404,107 +$4,826,591 $2.79 160
2022 Q1 108,535,070 $620,478,626 -$95,435,236 $5.72 176
2021 Q4 117,646,567 $1,073,655,355 +$78,398,633 $9.13 192
2021 Q3 108,488,554 $1,160,926,758 +$41,634,303 $10.69 189
2021 Q2 103,864,409 $1,612,145,175 +$202,378,763 $15.52 182
2021 Q1 89,846,972 $1,456,395,898 -$11,223,795 $16.21 186
2020 Q4 90,262,699 $1,910,380,366 +$26,526,144 $21.16 180
2020 Q3 90,857,946 $1,346,585,988 +$33,105,054 $14.82 177
2020 Q2 88,614,685 $1,334,393,703 -$51,210,796 $14.71 185
2020 Q1 92,095,623 $1,081,183,715 -$131,875,186 $11.74 186
2019 Q4 99,047,059 $2,326,444,060 +$183,809,453 $23.50 194
2019 Q3 91,435,188 $1,691,767,958 -$43,730,310 $18.50 175
2019 Q2 93,875,302 $1,744,712,239 +$2,233,456 $18.59 170
2019 Q1 92,662,760 $2,264,521,795 +$28,820,026 $24.44 189
2018 Q4 91,350,119 $2,369,031,974 +$92,438,916 $25.94 169
2018 Q3 87,463,202 $2,768,171,136 +$131,977,881 $31.65 187
2018 Q2 77,152,541 $2,997,578,965 +$216,890,926 $38.85 192
2018 Q1 72,567,037 $2,001,875,074 +$342,791,800 $27.60 149
2017 Q4 60,500,377 $1,095,067,241 +$103,341,807 $18.10 120
2017 Q3 63,406,329 $1,024,008,242 -$88,424,754 $16.15 101
2017 Q2 69,617,065 $964,195,934 +$47,548,351 $13.85 102
2017 Q1 71,661,852 $1,074,958,781 +$337,458,954 $15.00 98
2016 Q4 52,666,446 $689,938,271 +$4,719,852 $13.10 94
2016 Q3 51,265,727 $883,246,939 +$71,930,213 $17.23 88
2016 Q2 46,993,886 $848,220,501 +$35,391,534 $18.05 90
2016 Q1 45,017,464 $854,951,019 -$8,625,778 $18.99 98
2015 Q4 45,438,610 $1,214,308,493 +$39,761,438 $26.70 103
2015 Q3 43,669,932 $1,064,954,183 +$173,790,187 $24.40 101
2015 Q2 36,118,773 $1,125,171,985 +$319,523,410 $31.16 86
2015 Q1 26,445,484 $384,782,059 +$31,452,121 $14.55 68
2014 Q4 24,573,735 $247,206,453 +$2,536,942 $10.06 62
2014 Q3 24,229,222 $201,828,829 -$7,802,513 $8.33 56
2014 Q2 26,551,442 $327,060,299 +$69,901,807 $12.32 67
2014 Q1 20,801,929 $289,178,683 +$283,529,683 $13.91 39